Effects of dotarizine and flunarizine on chromaffin cell viability and cytosolic Ca2+

European Journal of Pharmacology

Volumn 366, Issue 2-3, 1999, Pages 309-317

  Novalbos, Jesús ^a,b   Abad Santos, Francisco ^a,b   Zapater, Pedro ^a,b   Cano Abad, María F ^b   Moradiellos, Javier ^a   Sánchez García, Pedro ^b   García, Antonio G ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Ca2+, cytosolic; Chromaffin cell viability; Dotarizine; Flunarizine

Indexed keywords

ASTEMIZOLE; CALCIUM ANTAGONIST; DOTARIZINE; FLUNARIZINE; FLUSPIRILENE; LIDOFLAZINE; NIFEDIPINE; PENFLURIDOL; PIPERAZINE; PIPERAZINE DERIVATIVE; PROPRANOLOL; VERAPAMIL; VERATRIDINE;

ANIMAL CELL; ARTICLE; CATTLE; CELL DAMAGE; CELL PROTECTION; CHROMAFFIN CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG TOXICITY; MIGRAINE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BENZHYDRYL COMPOUNDS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CATTLE; CELL DEATH; CELL MEMBRANE; CELL SURVIVAL; CHROMAFFIN CELLS; CYTOSOL; FLUNARIZINE; LIPID BILAYERS; PIPERAZINES; POTASSIUM; VERATRIDINE;

EID: 0033001111     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00916-9     Document Type: Article

References (36)

1. Ashton D., Willems R., Marrannes R., Janssen P.A. Extracellular ions during veratridine-induced neurotoxicity in hippocampal slices: neuroprotective effects of flunarizine and tetrodotoxin. Brain Res. 528:1990;212-222.
2. Binnie C.D., De Beukelaar F., Meijer J.W.A., Meinardi H., Overweg J., Wauquier A., Van Wieringen A. Open dose ranging trial of flunarizine as add-on therapy in epilepsy. Epilepsia. 26:1985;424-428.
3. Brasó, A., Cartheuser, C., Sacristán, A., Ortíz, J.A., 1989. Dotarizine, a promising N-benhydrylpiperazine for migraine prophylaxis due to an additional antiserotoninergic effect. 4th Int. Symp. Calcium Antagonists. Pharmacol. Clin. Res., Florence, 261.
4. 1 receptors. XIIth Int. Congr. Pharmacol. Montreal, Canada.
5. Brasó A., Martínez L., Planas J.M., Cartheuser C.F., Sacristan A., Ortíz J.A. Pharmacological profile and actions of dotarizine as a prophylactic antimigraine drug. J. Neurol. 243(suppl. 2,6):1996;531. Abst.
6. 2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. J. Cereb. Blood Flow Metab. 15:1995;513-518.
7. Cartheuser C.F., Brasó A., Sacristán A., Ortíz J.A. Effects of dotarizine on peripheral and pulmonary circulation and cardiac dynamics in dogs. Pharmacology. 48:1994;187-193.
8. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
9. De Ryck M., Van Reempts J., Borgers M., Wauquier A., Janssen P.A.J. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke. 20:1989;1383-1390.
10. Galiano L., Matias-Guiu J., Horga J.F., Martín R., Falip R., Montiel I. Dotarizine: a double-blind trial in prophylactic treatment of migraine. Cephalalgia. 13:1993;251. suppl. 13.
11. Goadsby P.J., Olesen J. Diagnosis and management of migraine. Br. Med. J. 312:1996;1279-1283.
12. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
13. Gubert S., Brasó M.A., Sacristán A., Ortíz J.A. Synthesis of some N-benzhydryl-piperazine derivatives. Arzneimitz-Forsch. Drug. Res. 37:1987;1103-1107.
14. Koh J.Y., Cotman C.W. Programmed cell death: its possible contribution to neurotoxicity mediated by calcium channel antagonists. Brain Res. 587:1992;233-240.
15. 2+ determine nerve growth factor dependence of sympathetic ganglion cells. Proc. Natl. Acad. Sci. USA. 86:1989;6421-6425.
16. 2+ channel antagonists': lipophilicity, inhibition, and recovery of secretion in chromaffin cells. Eur. J. Pharmacol. 325:1997;109-119.
17. Livett B.G. Adrenal medullary chromaffin cells in vitro. Physiol. Rev. 64:1984;1103-1161.
18. López M.G., Artalejo A.R., García A.G., Neher E., García-Sancho J. Veratridine induces oscillations of cytosolic calcium and membrane potential in bovine chromaffin cells. J. Physiol. 489:1995;15-27.
19. Lynch G., Seubert P. Links between long-term potentiation and neuropathology. An hypothesis involving calcium-activated proteases. Ann. N.Y. Acad. Sci. 568:1989;171-180.
20. 2+ oscillations induced by veratridine. Eur. J. Pharmacol. 270:1994;331-339.
21. 1 receptor, in bovine adrenal medulla. Mol. Pharmacol. 47:1995;40-50.
22. Micheli F., Pardal M.F., Gatto M., Torres M., Paradiso G., Parera I.C., Giannaula R. Flunarizine and cinnarizine-induced extrapyramidal reactions. Neurology. 37:1987;881-884.
23. 2 receptors. Eur. J. Pharmacol. 332:1997;183-193.
24. Moro M.A., López M.G., Gandía L., Michelena P., García A.G. Separation and culture of living adrenaline- and noradrenaline-containing cells from bovine adrenal medullae. Anal. Biochem. 185:1990;243-248.
25. Neher, E. 1989. Combined fura-2 and patch-clamp measurements in rat peritoneal mast cells. In: Sellin, L.C., Libelius, R., Thesleff, S. (Eds.), Neuromuscular Junctions. Elsevier, Amsterdam, pp. 65-76.
26. 2+ channel gene CACNL1A4. Cell. 87:1996;543-552.
27. 2+ mediated neuronal death in rat brain neuronal cultures by veratridine: protection by flunarizine. Mol. Pharmacol. 36:1989;525-531.
28. 2+ channels. J. Pharmacol. Exp. Ther. 255:1990;1117-1122.
29. + channels involved in neuronal cell death. Protection by flunarizine. Life Sci. 48:1991;1881-1893.
30. Rich K.M., Hollowell J.P. Flunarizine protects neurons from death after axotomy or NGF deprivation. Science. 248:1990;1419-1421.
31. Scheufler E., Peters T. Phosphatidylserine monolayers as models for drug uptake into membranes and tissue. Cell Biol. Int. Reports. 14:1990;381-388.
32. 2+ movements and contractile responses in vascular smooth muscle Eur. J. Pharmacol. 239:1993;75-81.
33. Thomas P.G., Seelig J. Binding of the calcium antagonist flunarizine to phosphatidylcholine bilayers: charge effects and thermodynamics. Biochem. J. 291:1993;397-402.
34. Todd P.A., Benfield P. Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs. 38:1989;481-499.
35. Villarroya M., Gandía L., Lara B., Albillos A., López M.G., García A.G. Dotarizine versus flunarizine as calcium antagonists in chromaffin cells. Br. J. Pharmacol. 114:1995;369-376.
36. Welch K.M.A. Drug therapy of migraine. N. Engl. J. Med. 329:1993;1476-1483.